US Bancorp
NGM

US Bancorp’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

US Bancorp’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,751
Closed -$11K – 4138
2023
Q4 		$11K Buy
+12,751
New +$11.2K ﹤0.01% 3297
2023
Q3 		– Sell
-452
Closed -$1.17K – 4143
2023
Q2 		$1.17K Sell
452
-1,209
-73% -$4.31K ﹤0.01% 3786
2023
Q1 		$6.78K Buy
1,661
+472
+40% +$2.18K ﹤0.01% 3423
2022
Q4 		$5.97K Buy
1,189
+1,051
+762% +$6.59K ﹤0.01% 3457
2022
Q3 		$2K Buy
138
+73
+112% +$1.11K ﹤0.01% 3885
2022
Q2 		$1K Sell
65
-421
-87% -$5.83K ﹤0.01% 4038
2022
Q1 		$7K Buy
486
+177
+57% +$2.76K ﹤0.01% 3527
2021
Q4 		$5K Buy
309
+203
+192% +$3.9K ﹤0.01% 3678
2021
Q3 		$2K Buy
+106
New +$2.33K ﹤0.01% 3940
2021
Q2 		– Sell
-270
Closed -$8K – 4098
2021
Q1 		$8K Hold
270
– – ﹤0.01% 3387
2020
Q4 		$8K Buy
+270
New +$5.91K ﹤0.01% 3283
2020
Q3 		– Sell
-45
Closed -$1K – 3887
2020
Q2 		$1K Buy
+45
New +$860 ﹤0.01% 3673

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

US Bancorp's NGM Position: Q1 2024 in Review

US Bancorp sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 12,751 shares — an estimated $11K sold.

US Bancorp first reported a position in NGM in Q2 2020 and held it in 12 quarters. The position peaked at $11K in Q4 2023. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • US Bancorp reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • US Bancorp sold 12,751 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $11K.
  • US Bancorp first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • US Bancorp's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $11K in Q4 2023.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.